Amazon brings genetic testing to your front door

Genetic testing can determine a parent's risk of having children effected by cystic fibrosis (CF) and spinal muscular atrophy (SMA). Most genetic testing involves giving a blood sample then waiting weeks for results, but Good Start Genetics has developed a VeriYou genetic test for easy access through Amazon.

The VeriYou test takes the saliva of both parents and tests for both CF and SMA. This can be crucial knowledge, with one in 19 Americans a carrier of CF or SMA, which means the child of two carrier parents has a 25 percent chance of having these dangerous diseases.  

Where before patients had to contact their physician to order a genetic test, VeriYou gives test quickly and accurately.

"Despite widespread clinical availability of carrier testing, too few couples are getting screened today to promote a healthy pregnancy," said Jeffrey R. Luber, President and CEO of Good Start Genetics. "By bringing clinical-grade NGS testing to Amazon for $149, we believe we can vastly improve awareness, access, and broaden the adoption of carrier screening for millions of couples starting a family. With Amazon's analytics and information engine, we have the opportunity to bring the right test to the right individual at the right time—a key promise of personalized medicine."

"Having had the privilege to lead several large product marketing initiatives at Amazon over the years, and helping grow several multi-million dollar franchises online at Amazon, we're excited to be working exclusively with Good Start Genetics as the first Amazon direct partner for genetic testing," said Nater Youngchild, Principal with Seattle-based Resolut Partners, digital stewards for new product verticals within Amazon. "We're thrilled that Good Start's next-generation sequencing tests will be made more widely available at price points never previously seen for advanced testing of this kind." 

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.